Conference Call on Wednesday, March 7, 11:00 A.M. ET
RICHMOND, VA., March 6 /CNW/ - Insmed (NASDAQ: INSM) announced that it
will host a conference call on Wednesday, March 7 at 11:00 a.m. (ET) to
discuss the litigation settlement with Genentech and Tercica, and other
Among participants on the call will be Geoffrey Allan, Ph.D., president
and CEO of Insmed and Kevin Tully, Executive Vice President and CFO.
Interested investors can listen to the call over the Internet from
Insmed's investor relations website at www.insmed.com or by dialing (888)
802-2225 (domestic) or (913) 312-1268 (international).
A telephonic replay of the call will be available for two weeks, by
dialling (888) 203-1112 (domestic) or (719) 457-0820 (international). The
passcode # is 4396908.
A web replay of the call will be available through the corporate website.
Insmed Inc. is a biopharmaceutical company focused on the development and
commercialization of drug candidates for the treatment of metabolic diseases
and endocrine disorders with unmet medical needs. For more information, please
Insmed Safe Harbor Statement
Statements included within this press release, which are not historical
in nature, may constitute forward-looking statements for purposes of the safe
harbor provided by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements in this press release include, but are not limited
to, statements regarding business strategies, growth opportunities for
approved or proposed products, plans and objectives of management. Such
forward-looking statements are subject to numerous risks and uncertainties,
including risks that our product candidates may fail in clinical trials or may
not be successfully marketed, we may lack financial resources to complete
development of product candidates, we may be unable to raise additional
financing necessary to continue current operations competing products may be
more successful, demand for new pharmaceutical products may decrease and the
biopharmaceutical industry may experience negative market trends. As a result
of these and other risks and uncertainties, actual results may differ
materially from those described in this press release. For further information
with respect to factors that could cause actual results to differ from
expectations, reference is made to reports filed by the Company with the
Securities and Exchange Commission under the Securities Exchange Act of 1934,
as amended. The forward-looking statements made in this release are made only
as of the date hereof and Insmed disclaims any intention or responsibility for
updating predictions or financial guidance contained in this release.
For further information:
For further information: Insmed Jody LoMenzo, 804-565-3041